| NF-1, Nutraceutical Intervention (NCT05363267) | Masonic Cancer Center, University of Minnesota | 2022-07-06 |
| Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1 (NCT05196854) | Murdoch Childrens Research Institute | 2022-05-25 |
| Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1 (NCT05377008) | Virginia Commonwealth University | 2022-05-13 |
| Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 (NCT05238909) | Ann & Robert H Lurie Children's Hospital of Chicago | 2022-03-04 |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas (NCT04750928) | National Cancer Institute (NCI) | 2021-11-29 |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (NCT04924608) | AstraZeneca | 2021-11-19 |
| HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (NCT05331105) | Shanghai Kechow Pharma, Inc. | 2021-10-18 |
| NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (NCT05005845) | NFlection Therapeutics, Inc. | 2021-09-29 |
| Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1 (NCT05677594) | Johns Hopkins University | 2021-07-01 |
| Natural History Study of Cutaneous Neurofibromas in People With NF1 (NCT05581511) | Johns Hopkins University | 2021-06-28 |
| Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial (NCT04879160) | National Cancer Institute (NCI) | 2021-05-12 |
| Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 (NCT04941027) | Stanford University | 2021-05-07 |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 (NCT04954001) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2021-03-26 |
| Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial (NCT04561765) | Yale University | 2021-03-01 |
| Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN) (NCT04774289) | National Cancer Institute (NCI) | 2021-02-24 |
| Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 (NCT04481048) | Children's Hospital Medical Center, Cincinnati | 2021-02-23 |
| Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 (NCT04860362) | University of Wisconsin, Milwaukee | 2021-01-29 |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) (NCT04590235) | AstraZeneca | 2020-12-16 |
| Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 (NCT04856514) | University of Wisconsin, Milwaukee | 2020-12-05 |
| NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (NCT04435665) | NFlection Therapeutics, Inc. | 2020-08-21 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors (NCT03433183) | Sarcoma Alliance for Research through Collaboration | 2019-10-02 |
| Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation (NCT03981510) | University of Aarhus | 2019-06-13 |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib (NCT03741101) | Region Skane | 2019-06-10 |
| Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 (NCT04991428) | University of Manchester | 2019-02-22 |
| From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 (NCT03826940) | University of Coimbra | 2019-02-19 |
| Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 (NCT04481035) | Children's Hospital Medical Center, Cincinnati | 2019-01-15 |
| A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) (NCT06379230) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2019-01-01 |
| Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials (NCT03531814) | National Cancer Institute (NCI) | 2018-10-23 |
| Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 (NCT03820778) | Children's National Research Institute | 2018-07-12 |
| Non-invasive Stimulation in Neurofibromatosis Type 1 (NCT03310996) | University of Manchester | 2017-10-13 |
| RASopathy Biorepository (NCT04395495) | Children's Hospital Medical Center, Cincinnati | 2017-06-27 |
| Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) (NCT03109301) | National Cancer Institute (NCI) | 2017-04-07 |
| Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 (NCT03090971) | Fundação Educacional Serra dos Órgãos | 2017-02-15 |
| Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II (NCT02728388) | Donald Basel | 2016-09-16 |
| Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms (NCT03298438) | University Hospital, Brest | 2016-07-15 |
| Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 (NCT02680431) | Juha Peltonen | 2016-01-01 |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) (NCT02544022) | National Cancer Institute (NCI) | 2015-11-13 |
| Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 (NCT02153931) | National Cancer Institute (NCI) | 2014-05-31 |
| Neurofibromatosis (NF) Registry Portal (NCT01885767) | The Children's Tumor Foundation | 2012-06-01 |
| Modifying Genes in Neurofibromatosis 1 (NCT01650142) | Assistance Publique - Hôpitaux de Paris | 2012-05-01 |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors (NCT01362803) | National Cancer Institute (NCI) | 2011-09-21 |
| Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis (NCT01777451) | Universitaire Ziekenhuizen KU Leuven | 2010-12-01 |
| Genetic Evaluation of NF1 and Scoliosis Patients (NCT01776125) | University of Minnesota | 2010-08-01 |
| Medical Treatment of "High-Risk" Neurofibromas (NCT00846430) | Corewell Health West | 2008-10-01 |
| Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas (NCT00076102) | National Cancer Institute (NCI) | 2004-07-21 |